155 related articles for article (PubMed ID: 11060749)
21. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
23. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
McKeage MJ; Mistry P; Ward J; Boxall FE; Loh S; O'Neill C; Ellis P; Kelland LR; Morgan SE; Murrer B
Cancer Chemother Pharmacol; 1995; 36(6):451-8. PubMed ID: 7554035
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
[TBL] [Abstract][Full Text] [Related]
25. Studies on cellular accumulation of satraplatin and its major metabolite JM118 and their interactions with glutathione.
Kostrhunova H; Kasparkova J; Gibson D; Brabec V
Mol Pharm; 2010 Dec; 7(6):2093-102. PubMed ID: 20936822
[TBL] [Abstract][Full Text] [Related]
26. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
27. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.
Samimi G; Howell SB
Cancer Chemother Pharmacol; 2006 Jun; 57(6):781-8. PubMed ID: 16170571
[TBL] [Abstract][Full Text] [Related]
28. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
Sternberg CN; Whelan P; Hetherington J; Paluchowska B; Slee PH; Vekemans K; Van Erps P; Theodore C; Koriakine O; Oliver T; Lebwohl D; Debois M; Zurlo A; Collette L;
Oncology; 2005; 68(1):2-9. PubMed ID: 15741753
[TBL] [Abstract][Full Text] [Related]
29. Satraplatin for the therapy of castration-resistant prostate cancer.
Sonpavde G; Sternberg CN
Future Oncol; 2009 Sep; 5(7):931-40. PubMed ID: 19792961
[TBL] [Abstract][Full Text] [Related]
30. Satraplatin. BMS 182751, BMY 45594, JM 216.
Drugs R D; 2002; 3(1):67-71. PubMed ID: 11881537
[No Abstract] [Full Text] [Related]
31. Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.
Theiner S; Varbanov HP; Galanski MS; Egger AE; Berger W; Heffeter P; Keppler BK
J Biol Inorg Chem; 2015 Jan; 20(1):89-99. PubMed ID: 25413442
[TBL] [Abstract][Full Text] [Related]
32. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
Raynaud FI; Odell DE; Kelland LR
Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
[TBL] [Abstract][Full Text] [Related]
33. Lobaplatin: a new antitumour platinum drug.
McKeage MJ
Expert Opin Investig Drugs; 2001 Jan; 10(1):119-28. PubMed ID: 11116285
[TBL] [Abstract][Full Text] [Related]
34. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317
[TBL] [Abstract][Full Text] [Related]
35. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
36. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.
Judson I; Cerny T; Epelbaum R; Dunlop D; Smyth J; Schaefer B; Roelvink M; Kaplan S; Hanauske A
Ann Oncol; 1997 Jun; 8(6):604-6. PubMed ID: 9261531
[TBL] [Abstract][Full Text] [Related]
38. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461
[TBL] [Abstract][Full Text] [Related]
39. Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.
Bell DN; Liu JJ; Tingle MD; Rattel B; Meyer TU; McKeage MJ
Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1440-6. PubMed ID: 18671714
[TBL] [Abstract][Full Text] [Related]
40. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
